Search

Displaying results 1121 - 1130 of 7674 in total
  1. Drug

    Cetalkonium

    go.drugbank.com/drugs/DB11583
    ApprovedWithdrawn

    [L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113] … [A27143] It is a quaternary ammonium salt that acts as an antiseptic against a variety of bacteria and fungi.

  2. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).

  3. Drug

    Minaprine

    go.drugbank.com/drugs/DB00805
    Approved

    Minaprine is an amino-phenylpyridazine antidepressant reported to be relatively free of cardiotoxicity, drowsiness, and weight gain.

  4. Drug

    Tetrabenazine

    go.drugbank.com/drugs/DB04844
    Approved

    FDA approved on August 15, 2008. … A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders.

  5. Drug

    Propiomazine

    go.drugbank.com/drugs/DB00777
    Approved

    Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia.

    Categories: Dopamine D2 Receptor Antagonists
  6. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    [F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby

  7. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.

  8. Drug

    Tavaborole

    go.drugbank.com/drugs/DB09041
    Approved

    Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes … Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).

  9. Drug

    Moxetumomab pasudotox

    go.drugbank.com/drugs/DB12688
    ApprovedInvestigational

    [A38864] It was developed by Astra Zeneca and FDA approved on September 13, 2018, after being granted the status of Fast Track, Priority Review and Orphan Drug designations.[L4568] … [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.

  10. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions. … [A241045] In December 2022, ublituximab was approved by the US FDA for the treatment of relapsing forms of multiple sclerosis, becoming the first and only anti-CD20 monoclonal antibody for multiple sclerosis